Dear Shareholder,

You may have noted the press release that came out today regarding the upgrade of our Ultra High Throughput (UHT) machine, and I wanted to take this opportunity to highlight some of the important issues surrounding this improvement.  As you may know, we use the Beckman Coulter UHT machine to process our samples, both for our services in the Forensic market and in the Consumer market. Our services for DNAWitness™, RETINOME™ and ANCESTRYbyDNA™ should have a margin improvement as a result of this new 48-plex panel system. We anticipate a four-fold increase in productivity and nearly a 50% reduction in our material costs.

This means that we will be able to perform more assays in our research for less money, and we will be able to increase our margins for our service line. We will however, pass on some of those savings to our customers in the Genotyping area, where cost reduction is a primary driver for increased revenues. This also means that we will be able to take on more high-volume cases, which we are aggressively pursuing.

Our continued improvement of operations, fine tuning of assays, and purchase of new equipment will help us focus on all the new opportunities that we have recently taken on, including our new drug licensing product PT-401 (our Super EPO) and our recent acquisition of Trace Genetics in San Francisco, Calif. We continue seeking to build shareholder value and to increase revenues, and we will continue to seek acquisitions, licenses and partnerships to expand our capacities, add revenue and improve our market perception.

Beckman Coulter is an important partner in our development, and we are attending a Forensic conference in Hong Kong in August, to present our work on the UHT machines in a general talk and in a workshop. Beckman has set up several strategic meetings with Chinese industry and government officials who are interested in using our technology along with the Beckman UHT system.

All of us appreciate your continued support and interest in DNAPrint genomics, Inc. Thank you.